Athenex Pharmaceutical Division Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Athenex Pharmaceutical Division Llc Pharmaceutical Import Records from India — 2 Products, $650.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Athenex Pharmaceutical Division Llc — Pharmaceutical Importer Profile (2026) | 2 Products, $650.0K Trade | TransData Nexus

Athenex Pharmaceutical Division Llc

Pharmaceutical Importer · United States · Diabetes & Endocrine Focus · $650.0K Total Trade · DGFT Verified

Athenex Pharmaceutical Division Llc is a pharmaceutical importer based in United States with a total trade value of $650.0K across 2 products in 2 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Athenex Pharmaceutical Division Llc sources from 1 verified Indian supplier, with Gland Pharma Limited accounting for 100.0% of imports.

Athenex Pharmaceutical Division Llc — Import Portfolio & Supplier Network

Athenex Pharmaceutical Division Llc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Athenex Pharmaceutical Division Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$1.6M	33	100.0%

Athenex Pharmaceutical Division Llc sources from 1 verified Indian supplier across 11 distinct formulations. The sourcing is highly concentrated — Gland Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Levothyroxine sodium for injection	$300.0K	6
Levetiracetam in 0.82% sodium chloride	$256.8K	6
Ondansetron injection 4MG/2ML (2MG/ML)	$250.0K	5
Azithromycin for injection USP	$200.0K	4
Zoledronic acid injection 4MG/100ML	$145.0K	3
Levetiracetam in 0.75% sodium chloride	$124.8K	3
Azithromycin for injection USP 500MG	$100.0K	2
Ketorolac tromethamine injection USP	$50.0K	1
Caspofungin acetate for injection	$50.0K	1
Levothyroxine sodium for injection	$50.0K	1
Tranexamic acid injection 100MG/ML, 10ML	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Levothyroxine	Diabetes & Endocrine	$350.0K	7	0.5%	14
2	Azithromycin	Antibiotics	$300.0K	6	0.2%	14

Athenex Pharmaceutical Division Llc imports 2 pharmaceutical products across 2 categories into United States totaling $650.0K.

Athenex Pharmaceutical Division Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Athenex Pharmaceutical Division LLC (APD) is a U.S.-based pharmaceutical company specializing in the development, manufacturing, and commercialization of specialty injectable products. As a subsidiary of Athenex, Inc., a global biopharmaceutical company dedicated to cancer therapies, APD focuses on supplying the U.S. hospital market with high-quality medications that address unmet or underserved needs. The company is headquartered in Schaumburg, Illinois, and operates under the parent company's broader mission to improve patient outcomes through innovative treatments.

APD's product portfolio includes a range of injectable medications, such as Levothyroxine Sodium for Injection, which was launched in December 2018. This product exemplifies APD's commitment to providing essential therapies to healthcare providers and patients. The company's strategic focus on specialty injectables positions it as a key player in the U.S. pharmaceutical distribution landscape, catering to the specific needs of hospital and clinical settings.

2Distribution Network

Athenex Pharmaceutical Division LLC's distribution network is designed to ensure efficient delivery of its injectable products to healthcare facilities across the United States. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are supported by its parent company's global supply chain infrastructure. This infrastructure facilitates the timely and reliable distribution of medications to hospitals, outpatient clinics, and physician offices nationwide. APD's strategic partnerships with major distributors and group purchasing organizations (GPOs) further enhance its reach and operational efficiency.

3Industry Role

In the U.S. pharmaceutical supply chain, Athenex Pharmaceutical Division LLC functions primarily as a specialty pharmaceutical company focused on the development and commercialization of injectable medications. By leveraging its parent company's resources and expertise, APD plays a significant role in supplying critical therapies to the hospital and clinical markets. Its emphasis on specialty injectables allows it to address specific therapeutic needs, positioning the company as a valuable partner to healthcare providers seeking reliable and high-quality pharmaceutical products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Athenex Pharmaceutical Division Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Athenex Pharmaceutical Division LLC's sourcing strategy exhibits a high degree of concentration, with a total import value of $650,000 USD from India across 13 shipments, all sourced from a single supplier, GLAND PHARMA LIMITED. This single-source dependency may present risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent sourcing from GLAND PHARMA LIMITED suggests a stable and reliable relationship, potentially mitigating some of these risks. The company's focus on a limited number of products—Levothyroxine and Azithromycin—further concentrates its sourcing strategy, which could impact its ability to diversify its supplier base and product offerings.

2Supply Chain Resilience

The resilience of Athenex Pharmaceutical Division LLC's supply chain is closely tied to its exclusive reliance on GLAND PHARMA LIMITED for the importation of its injectable products. This singular sourcing approach may limit the company's flexibility in responding to supply chain disruptions. The lack of publicly available information regarding backup suppliers or alternative sourcing strategies indicates a potential vulnerability in the supply chain. Additionally, the company's focus on a narrow range of formulations imported from India suggests limited diversification, which could further impact its ability to adapt to changing market conditions or regulatory challenges.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drug applications, including those for generic medications sourced from countries like India. The approval pathway for Indian generics involves submitting an Abbreviated New Drug Application (ANDA) to the FDA, demonstrating that the generic product is bioequivalent to the reference listed drug and meets all applicable quality standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Manufacturers must obtain FDA approval for each drug product, which includes demonstrating compliance with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from other regulatory bodies, such as the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), provided they meet FDA standards. Additionally, wholesale distributors must obtain appropriate state licenses to operate legally within the U.S. market.

Athenex Pharmaceutical Division Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Athenex Pharmaceutical Division LLC's product strategy focuses on specialty injectable medications, particularly in the therapeutic areas of Diabetes & Endocrine and Antibiotics. The company's imports from India, including Levothyroxine and Azithromycin, align with this focus, addressing critical needs in hospital and clinical settings. The market demand for these products is driven by the necessity for reliable and effective treatments for thyroid disorders and bacterial infections, respectively. By concentrating on these therapeutic areas, APD aims to fulfill specific gaps in the U.S. pharmaceutical market, providing essential therapies to healthcare providers and patients.

2Sourcing Profile

Athenex Pharmaceutical Division LLC's sourcing strategy emphasizes the procurement of generic injectable drugs from India, focusing on formulations that meet FDA standards and address specific therapeutic needs. The company's reliance on a single supplier, GLAND PHARMA LIMITED, suggests a strategic choice to maintain consistency and quality in its product offerings. However, this approach also indicates limited diversification in its supplier base, which could impact the company's ability to adapt to changes in the supply chain or market dynamics.

3Market Positioning

Seller's Guide — How to Become a Supplier to Athenex Pharmaceutical Division Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Athenex Pharmaceutical Division LLC's supply chain, particularly if they can offer competitive pricing, consistent quality, and reliable delivery schedules. Diversifying APD's supplier base could enhance its supply chain resilience and operational flexibility, potentially leading to more favorable terms and expanded market reach. For Indian exporters, establishing partnerships with APD could provide access to the U.S. hospital and clinical markets, leveraging the company's established distribution networks and regulatory compliance.

2Requirements & Qualifications

Indian exporters seeking to supply Athenex Pharmaceutical Division LLC and the U.S. market must comply with FDA regulations, including obtaining appropriate import licenses and ensuring that their manufacturing facilities adhere to GMP standards recognized by the FDA. Products must undergo batch testing and stability studies to meet FDA requirements, and labeling must be in English, adhering to FDA guidelines. Additionally, compliance with serialization mandates, such as those outlined in the DSCSA, is necessary to facilitate tracking and tracing throughout the supply chain.

How to Approach

Frequently Asked Questions — Athenex Pharmaceutical Division Llc

What products does Athenex Pharmaceutical Division Llc import from India?

Athenex Pharmaceutical Division Llc imports 2 pharmaceutical products across 2 categories. Top imports: Levothyroxine ($350.0K), Azithromycin ($300.0K).

Who supplies pharmaceuticals to Athenex Pharmaceutical Division Llc from India?

Athenex Pharmaceutical Division Llc sources from 1 verified Indian suppliers. The primary supplier is Gland Pharma Limited (100.0% of imports, $1.6M).

What is Athenex Pharmaceutical Division Llc's total pharmaceutical import value?

Athenex Pharmaceutical Division Llc's total pharmaceutical import value from India is $650.0K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Athenex Pharmaceutical Division Llc focus on?

Athenex Pharmaceutical Division Llc imports across 2 categories. The largest: Diabetes & Endocrine (53.8%), Antibiotics (46.2%).

Get Full Athenex Pharmaceutical Division Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.